TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11086670

Group type: EXPERIMENTAL
Intervention: Life Support Engineering Ltd. (LSEL) mask
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Zvezda Enterprise (ZE) mask
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Duke prototype mask
Number of subjects: 10
Study: 8957641

Group type: EXPERIMENTAL
Intervention: Barrier cream with particles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moisturizer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Silicone-containing cream
Number of subjects: 0
Study: 1349458

Group type: EXPERIMENTAL
Intervention: Propranolol (20 or 40 mg/day)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Betaxolol (10 or 20 mg/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 3993545

Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg/day)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/day)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 29946115

Group type: EXPERIMENTAL
Intervention: Red palm olein
Number of subjects: 53

Group type: COMPARATOR
Intervention: Palm olein
Number of subjects: 53
Study: 29728195

Group type: EXPERIMENTAL
Intervention: Potassium oxalate mouthrinse (KO)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 375
Study: 27579360

Group type: EXPERIMENTAL
Intervention: Peyton's 4-Steps-Approach (PEY)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Peyton's 4-Steps-Approach without Step 3 (PMOD)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Standard model (STDM)
Number of subjects: 134
Study: 24051391

Group type: EXPERIMENTAL
Intervention: Propoven (Fresenius‐Kabi AG, Bad Homburg, Germany)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Diprivan (Astra‐Zeneca, Cheshire, United Kingdom)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Lipuro (B‐Braun, Melshungen AG, Germany)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Lidocaine 1% mixed with propofol formulations
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 217
Study: 24063608

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine plus piperaquine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 20304980

Group type: EXPERIMENTAL
Intervention: Benzydamine hydrochloride
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: 10% Lidocaine
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: 2% Lidocaine
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Normal Saline
Number of subjects: 372
Study: 18664256

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 222
Study: 16824239

Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine
Number of subjects: 72

Group type: COMPARATOR
Intervention: 0.25% ropivacaine
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 0.4% ropivacaine
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: All groups (including 0.25% levobupivacaine, 0.25% ropivacaine, and 0.4% ropivacaine)
Number of subjects: 72
Study: 12492710

Group type: EXPERIMENTAL
Intervention: One dose of daclizumab (2 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Two doses of daclizumab (2nd dose, 1 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Daclizumab levels of 1 micro g/mL or greater
Number of subjects: 12
Study: 10977382

Group type: EXPERIMENTAL
Intervention: Tobacco control activities in intervention communities
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Youth tobacco control activities in intervention communities
Number of subjects: 22

Group type: COMPARATOR
Intervention: Comparison communities
Number of subjects: 22
Study: 8771523

Group type: EXPERIMENTAL
Intervention: Povidone-iodine
Number of subjects: 3117

Group type: EXPERIMENTAL
Intervention: Silver nitrate
Number of subjects: 3117

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 3117

Group type: COMPARATOR
Intervention: Maternal vaginitis
Number of subjects: 3117
Study: 1591091

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment for 5 years
Number of subjects: 504

Group type: COMPARATOR
Intervention: Chemotherapy (six courses of cyclophosphamide, methotrexate and 5‐fluorouracil (CMF) followed by 4 courses of epirubicin)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Combination of chemotherapy and tamoxifen
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Concurrent or sequential use of chemotherapy and tamoxifen
Number of subjects: 504
Study: 30457209

Group type: EXPERIMENTAL
Intervention: Composite genetic risk score (GRS) based on 27 single nucleotide polymorphisms (SNPs)
Number of subjects: 1640

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 1640

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1640
Study: 28302387

Group type: EXPERIMENTAL
Intervention: Active transcranial direct-current stimulation (2 mA, 10 sessions over 2 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham transcranial direct-current stimulation (10 sessions over 2 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Active transcranial direct-current stimulation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham transcranial direct-current stimulation
Number of subjects: 40
Study: 25462207

Group type: EXPERIMENTAL
Intervention: Therapeutic harp sounds (30-40 minutes of prescriptive live therapeutic harp sounds)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Therapeutic harp sounds
Number of subjects: 92
Study: 23656489

Group type: EXPERIMENTAL
Intervention: Feedback interventions (Fb)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 133
Study: 21860048

Group type: EXPERIMENTAL
Intervention: Compensatory cognitive training (CT)
Number of subjects: 89
Study: 19650422

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT) method
Number of subjects: 295

Group type: COMPARATOR
Intervention: Burch suspension
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Both methods (Burch and TVT)
Number of subjects: 295
Study: 17263741

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 113

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Sevoflurane (0-24 months)
Number of subjects: 113
Study: 15209619

Group type: EXPERIMENTAL
Intervention: Cisapride 5 mg orally three times daily for 12 weeks (dose doubled after 4 weeks if no improvement)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo three times daily for 12 weeks (dose doubled after 4 weeks if no improvement)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 11136204

Group type: EXPERIMENTAL
Intervention: High UPA score practices
Number of subjects: 18414

Group type: COMPARATOR
Intervention: Low UPA score practices
Number of subjects: 18414
Study: 9588577

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pravastatin + Cyclosporine
Number of subjects: 20
Study: 8019118

Group type: EXPERIMENTAL
Intervention: 2% nedocromil sodium
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 2731558

Group type: EXPERIMENTAL
Intervention: Full contrast dose (282 mg I/kg body weight)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Half contrast dose (141 mg I/kg body weight)
Number of subjects: 60
Study: 4381149

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnesium pemoline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31654654

Group type: EXPERIMENTAL
Intervention: Flavanol-rich cocoa beverage (FC)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Non-flavanol containing beverage (NF)
Number of subjects: 14
Study: 31295390

Group type: EXPERIMENTAL
Intervention: Manual toothbrush with CrissCross and tapered bristle technology (Oral-B CrossAction Ultrathin); brushed twice daily for 4 weeks.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional flat-trim design and regular non-tapered bristles (Oral-B Indicator Soft 35); brushed twice daily for 4 weeks.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups (tapered and control toothbrushes); assessed for plaque reduction using TMQHPI.
Number of subjects: 100
Study: 28045890

Group type: EXPERIMENTAL
Intervention: Postal pedometer intervention
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: Nurse-supported pedometer intervention
Number of subjects: 1023

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1023
Study: 26176621

Group type: EXPERIMENTAL
Intervention: Housing First with Intensive Case Management (HF with ICM)
Number of subjects: 378
Study: 23384637

Group type: EXPERIMENTAL
Intervention: High-school education
Number of subjects: 2951

Group type: EXPERIMENTAL
Intervention: Academic education
Number of subjects: 2951

Group type: EXPERIMENTAL
Intervention: Blue collar occupation
Number of subjects: 2951

Group type: COMPARATOR
Intervention: Academic/white collar occupations
Number of subjects: 2951
Study: 21303430

Group type: EXPERIMENTAL
Intervention: 16μg lubiprostone
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: 32μg lubiprostone
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: 48μg lubiprostone
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: 48μg lubiprostone (patients with IBS)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 19179885

Group type: EXPERIMENTAL
Intervention: PBP (ProBioPlus DDS, UAS Laboratories)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: CUL (Culturelle, ConAgra)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (dilute preparation of Pregestamil formula)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: PBP
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: CUL
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 17658695

Group type: EXPERIMENTAL
Intervention: Freshmen-specific personalized normative feedback (PNF)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Assessment only control
Number of subjects: 316
Study: 14688021

Group type: EXPERIMENTAL
Intervention: Variant SULT1A1 genotype (638GA or AA)
Number of subjects: 1614

Group type: EXPERIMENTAL
Intervention: Variant SULT1A1 genotype (638GA or AA) in smokers
Number of subjects: 1614

Group type: EXPERIMENTAL
Intervention: Variant SULT1A1 genotype (638GA or AA) in non-smokers
Number of subjects: 1614

Group type: EXPERIMENTAL
Intervention: Variant SULT1A1 genotype (638GA or AA) with cumulative smoking dose
Number of subjects: 1614

Group type: EXPERIMENTAL
Intervention: Variant SULT1A1 genotype (638GA or AA) across histological subtypes
Number of subjects: 1614
Study: 11825322

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etodolac
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nimesulide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meloxicam
Number of subjects: 0
Study: 9331014

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (4-16 mg once-daily)
Number of subjects: 0
Study: 7944681

Group type: EXPERIMENTAL
Intervention: Amiodarone therapy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Not receiving amiodarone
Number of subjects: 67
Study: 2908757

Group type: EXPERIMENTAL
Intervention: Lidamidine hydrochloride
Number of subjects: 72
Study: 30109702

Group type: EXPERIMENTAL
Intervention: Active TFP block
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined TFP and LFC nerve blockade
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TFP block
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo TFP block
Number of subjects: 20
Study: 28972039

Group type: EXPERIMENTAL
Intervention: Galinpepimut-S with GM-CSF and Montanide
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control adjuvants (GM-CSF and Montanide alone)
Number of subjects: 41
Study: 25539281

Group type: EXPERIMENTAL
Intervention: Informational brochure
Number of subjects: 120
Study: 23206722

Group type: EXPERIMENTAL
Intervention: Transcutaneous posterior tibial nerve stimulation (TPTNS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham stimulation (placebo)
Number of subjects: 30
Study: 21964277

Group type: EXPERIMENTAL
Intervention: Citalopram (flexible doses) for up to 14 weeks
Number of subjects: 2876
Study: 19109962

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg) administered intravenously within 4 weeks of surgery and continued for 1 year
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 17821878

Group type: EXPERIMENTAL
Intervention: Baby Express newsletter
Number of subjects: 185

Group type: COMPARATOR
Intervention: Normal services only (control)
Number of subjects: 185
Study: 16343130

Group type: EXPERIMENTAL
Intervention: Individually-selected enhancement parameters for video
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptive enhancement (individually-tuned using a static image)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stronger contrast enhancement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unenhanced, over-enhanced, and degraded segments
Number of subjects: 0
Study: 12411229

Group type: EXPERIMENTAL
Intervention: Errorless learning
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conventional instruction
Number of subjects: 65
Study: 10467830

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1000 mg/day for 3 months)
Number of subjects: 10
Study: 7605028

Group type: EXPERIMENTAL
Intervention: Antishock overalls (ASO)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional antishock intensive care
Number of subjects: 30
Study: 2319316

Group type: EXPERIMENTAL
Intervention: Radiation therapy with adjuvant chemotherapy (CCNU, vincristine, and prednisone)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CCNU, vincristine, and prednisone) in patients with more extensive tumors
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Both groups (radiation therapy with and without chemotherapy)
Number of subjects: 233
Study: 536969

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg twice a day
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Bendrofluazide 2.5 mg twice a day
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Combination of propranolol and bendrofluazide
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 30651036

Group type: EXPERIMENTAL
Intervention: Udenafil 75 mg daily
Number of subjects: 138
Study: 31320603

Group type: EXPERIMENTAL
Intervention: Vacuum sealing drainage (VSD) treatment combined with skin flap transplantation and antibiotic bone cement
Number of subjects: 18
Study: 28396306

Group type: EXPERIMENTAL
Intervention: Web-based intervention for physical activity (PA) and fruit and vegetable intake (FVI) over 8 weeks.
Number of subjects: 493
Study: 25803642

Group type: EXPERIMENTAL
Intervention: Multivalent NoV VLP vaccine (genotypes GI.1/GII.4)
Number of subjects: 10
Study: 24210087

Group type: EXPERIMENTAL
Intervention: Cabozantinib (100 mg daily)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 21732905

Group type: EXPERIMENTAL
Intervention: HP-hMG
Number of subjects: 155

Group type: COMPARATOR
Intervention: rFSH
Number of subjects: 155
Study: 19565549

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment plus rheumatologic care program
Number of subjects: 181

Group type: COMPARATOR
Intervention: Rheumatologic care program
Number of subjects: 181
Study: 16782719

Group type: EXPERIMENTAL
Intervention: Adenosine (50 or 70 microg/kg/min) for 3 hours starting within 15 minutes of reperfusion therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15307977

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH), specifically dalteparin
Number of subjects: 28

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 28
Study: 11402974

Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg/day)
Number of subjects: 605

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 605
Study: 9124466

Group type: EXPERIMENTAL
Intervention: Ketoconazole (steroidogenic enzyme inhibitor)
Number of subjects: 0
Study: 8066317

Group type: EXPERIMENTAL
Intervention: Decontaminated vinyl urinary drainage bags (group E)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Weekly replaced vinyl urinary drainage bags (group C)
Number of subjects: 88
Study: 3113764

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) continuous infusion
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 30604373

Group type: EXPERIMENTAL
Intervention: TELE‐IBD system (self-testing every other week)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: TELE‐IBD system (self-testing weekly)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 222
Study: 29509614

Group type: EXPERIMENTAL
Intervention: Boss-Holzach-Matter self-reduction technique (BHM group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Spaso technique (Sp group)
Number of subjects: 60
Study: 26538205

Group type: EXPERIMENTAL
Intervention: COX-2 + PPI (celecoxib 200 mg twice daily + rabeprazole 20 mg once daily)
Number of subjects: 57

Group type: COMPARATOR
Intervention: COX-2 + placebo (celecoxib 200 mg twice daily + placebo)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: COX-2 + PPI
Number of subjects: 57

Group type: COMPARATOR
Intervention: COX-2 + placebo
Number of subjects: 57
Study: 24949820

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Incident delayed filling
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: No incident delayed filling
Number of subjects: 973

Group type: COMPARATOR
Intervention: Monthly treatment
Number of subjects: 973

Group type: COMPARATOR
Intervention: As needed treatment
Number of subjects: 973
Study: 22130905

Group type: EXPERIMENTAL
Intervention: Relapse prevention therapy (RPT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Specialist FEP care
Number of subjects: 81
Study: 21300221

Group type: EXPERIMENTAL
Intervention: Damon3 self-ligated brackets
Number of subjects: 62

Group type: COMPARATOR
Intervention: Synthesis conventional ligated brackets
Number of subjects: 62
Study: 19225121

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient (MM) supplementation (1-1.5 times the Recommended Dietary Allowance of vitamins A, B-6, B-12, C, folic acid, iron, zinc, and other nutrients) 6 d/wk from 3 to 24 mo of age
Number of subjects: 650

Group type: COMPARATOR
Intervention: Iron only in utero and Fe-A during childhood
Number of subjects: 650
Study: 16881095

Group type: EXPERIMENTAL
Intervention: Conservative interventions for lateral epicondylitis
Number of subjects: 349
Study: 12482641

Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (diet or metformin)
Number of subjects: 46
Study: 11395985

Group type: EXPERIMENTAL
Intervention: High calcium group (dairy food supplementation)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (no dairy food supplementation)
Number of subjects: 91
Study: 8383397

Group type: EXPERIMENTAL
Intervention: Lisinopril (2.5 mg o.d. initially, increased to 5 mg and 10 mg o.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Captopril (6.25 mg t.i.d. initially, increased to 12.5 mg and 25 mg t.i.d.)
Number of subjects: 0
Study: 3048076

Group type: EXPERIMENTAL
Intervention: Mashed potatoes
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: French bread
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rice
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Spaghetti
Number of subjects: 12
Study: 29204964

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXA)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 27340360

Group type: EXPERIMENTAL
Intervention: lafutidine (10 mg, twice daily)
Number of subjects: 53

Group type: COMPARATOR
Intervention: lansoprazole (30 mg, once daily)
Number of subjects: 53
Study: 26575100

Group type: EXPERIMENTAL
Intervention: 1 h of cycling at Fatmax (moderate-intensity aerobic exercise)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 16-week lifestyle intervention (dietary calorie restriction and exercise training)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1 h of cycling at Fatmax (moderate-intensity aerobic exercise) after lifestyle intervention
Number of subjects: 18
Study: 23554851

Group type: EXPERIMENTAL
Intervention: Clobazam 20 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Clonazepam 1 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Tolterodine 1 mg (active placebo)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cuff algometry
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intramuscular pain models
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Other pain models
Number of subjects: 16
Study: 20825071

Group type: EXPERIMENTAL
Intervention: Ranibizumab (Lucentis) administered in doses of 0.3 or 0.5 mg into the vitreous body
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 18223621

Group type: EXPERIMENTAL
Intervention: Low fat diet (<25% of energy from fat)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Moderate fat diet (28-32% of energy from fat)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: High fat diet (>35% of energy from fat)
Number of subjects: 305
Study: 16948370

Group type: EXPERIMENTAL
Intervention: Vidrion R (SS White)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Ketac‐Molar
Number of subjects: 245
Study: 12674340

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 7753

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 7753

Group type: EXPERIMENTAL
Intervention: Nephrolithiasis
Number of subjects: 7753

Group type: COMPARATOR
Intervention: Disease conditions
Number of subjects: 7753